Increased isoprostanoid levels in brain from murine model of Krabbe disease – Relevance of isoprostanes, dihomom-isoprostanes and neuroprostanes to disease severity

Cinzia Signorini^{a,*}, Venera Cardile^{b,**}, Giovanna Pannuzzo^b, Adriana Carol Eleonora Graziano^b, Thierry Durand^c, Jean-Marie Galano^c, Camille Oger^c, Silvia Leoncini^d, Alessio Cortelazzo^d, Jetty Chung-Yung Lee^e, Joussef Hayek^d, Claudio De Felice^{d,f}

^a Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy

^b Department of Biomedical and Biotechnological Sciences, Sect. of Physiology, University of Catania, Italy

^c Institut des Biomolécules Max Mousseron, (IBMM), UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, France

^d Child Neuropsychiatry Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy

^e The University of Hong Kong, School of Biological Sciences, Hong Kong Special Administrative Region

^f Neonatal Intensive Care Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy

ARTICLE INFO

Keywords:

Adrenic acid
Isoprostanes
Krabbe disease
Leukodystrophy
Murine models
Neuroprostanes
Oxidative stress

ABSTRACT

Krabbe disease (KD) is a rare and devastating pediatric leukodystrophy caused by mutations in the galactocerebrosidase (GALC) gene. The disease leads to impaired myelin formation and extensive myelin damage in the brain. Oxidative stress is implicated in the pathogenesis of KD but insofar few information is available.

The gray and white matter of the brain are rich in docosahexaenoic acid and adrenic acid respectively and under non-enzymatic oxidative stress, release isoprostanoids, i.e. F₄-neuroprostanes (F₄-NeuroPs) and F₂-dihomom-isoprostanes (F₂-dihomom-IsoPs).

In this study, the formation of isoprostanoids in brain tissue was investigated in a well-established KD mouse model (twitcher) that recapitulates the human pathology.

According to the genotype determinations, three groups of mice were selected: wild-type control mice (n = 13), heterozygotes mice (carriers of GALC mutations, n = 14) and homozygous twitcher mice (n = 13). Measurement of F₂-dihomom-IsoP and F₄-NeuroP levels were performed on whole brain tissue obtained at day 15 and day 35 of the life cycle.

Brain isoprostanoid levels were significantly higher in the twitcher mice compared to the heterozygous and wild-type control mice. However, F₂-dihomom-IsoP and F₄-NeuroP levels did not differ in brain of day 15 compared to day 35 of the heterozygote mice. Interestingly, isoprostanoid levels were proportionally enhanced with disease severity (F₂-dihomom-IsoPs, $\rho = 0.54$; F₄-NeuroPs, $\rho = 0.581$; P values ≤ 0.05 ; n = 13).

Our findings are the first to show the key role of polyunsaturated fatty acid oxidative damage to brain grey and white matter in the pathogenesis and progression of KD. This shed new insights on the biochemical indexes of KD progression, and potentially provide information for novel therapeutic targets.

1. Introduction

Krabbe disease (KD) is a rare autosomal recessive disorder

attributed to mutations in the galactosylceramidase (GALC) gene. It is also known as globoid cell leukodystrophy due to the presence of multinucleated macrophages (globoid cells) in the brain white matter

Abbreviations: 4-F₄-neuroP, 4(RS)-4-F₄-neuropropane; 10-F₄-NeuroP, 10-F₄-neuropropane epimers; 15-F₂-IsoP, 15-F₂-isopropane; AA, arachidonic acid; AdA, adrenic acid; D15, 15th day; D35, 35th day; DHA, docosahexaenoic acid; F₂-IsoPs, F₂-isoprostanes; F₂-dihomom-IsoPs, F₂-dihomom-isoprostanes; F₄-NeuroPs, F₄-neuroprostanes; GALC, galactosylceramidase; GC/NICI-MS/MS, gas chromatography/negative-ion chemical ionization tandem mass spectrometry; HRM, high resolution melting; KD, Krabbe disease; PUFA, polyunsaturated fatty acid; ROC, receiver operating characteristic

* Corresponding author.

** Corresponding author.

E-mail addresses: cinzia.signorini@unisi.it (C. Signorini), cardile@unict.it (V. Cardile), c.defelice@ao-siena.toscana.it (C. De Felice).

and leukodystrophy gliosis. As a consequence, GALC enzymatic deficiency occurs and the metabolite psychosine (galactosylsphingosine) is accumulated [1,2]. Furthermore, increased amounts in unmetabolized galactocerebroside have been proposed to be cytotoxic to oligodendrocytes, which are the myelin-producing cells of the central nervous system [3,4]. Nevertheless, the exact mechanism of such cytotoxicity has not yet been fully elucidated but latest report suggests to take part in activating the immune system and neuroinflammation [5].

Additionally, phospholipase A₂ activity has been showed to mediate psychosine-mediated accumulation of lysophosphatidylcholine and release arachidonic acid (AA), and subsequently cause oligodendrocyte cell death [6]. Also, increasing evidence strengthens the relevance of polyunsaturated fatty acids (PUFA), namely AA, as well as docosahexaenoic acid (DHA) and adrenic acid (AdA) to brain physiology and development [7–14].

Recently, brain fatty acid composition was investigated in KD using the twitcher mice [15] and it showed to be altered, which could reflect the underlying metabolic changes taking place during disease progression [16].

It is well known that the non-enzymatic oxidation of AA, DHA, and AdA, are involved in clinical and experimental neurological disease [17–19] by the generation of prostaglandin isomers termed isoprostanoids [20]. Oxidative stress stimulates reactive oxygen species (ROS)/free-radical mediated peroxidation of AA, DHA and AdA and consequently leads to the formation of isoprostanoids namely F₂-isoprostanes (F₂-IsoPs), F₄-neuroprostanes (F₄-NeuroPs) and F₂-dihomo-isoprostanes (F₂-Dihomo-IsoPs), respectively. Both isoprostanes (IsoPs) and neuroprostanes (NeuroPs) are well described biomarkers of oxidative stress and may participate in cellular signaling [21–24]. Moreover, F₄-NeuroPs and F₂-dihomo-IsoPs are advocated to be associated to gray and white brain matter oxidative damage, respectively [25,26]. Moreover, DHA is highly concentrated in neuronal membranes and F₄-NeuroPs are by far the most abundant products of DHA peroxidation in the brain [27], whereas AdA is ubiquitously distributed in the body, but also a specific component of myelin in the brain of primates [28].

To the best of our knowledge, the formation and role of isoprostanoids in KD are unknown despite oxidative stress related pathways have been proposed for therapeutic target [2,29–32].

The purpose of the study is to investigate the possible involvement of IsoPs, dihom-IsoPs and NeuroPs in the KD pathogenesis taking into account that DHA and AdA are specifically distributed in the brain and the distribution of these specific isoprostanoids derived from the non-enzymatic oxidation process is relevant to the disease progression.

2. Materials and methods

2.1. Animals

The animal handling protocol was approved by the Institutional Animal Care and Use Committee for this study in accordance with institutional guidelines for animal care and use (Project no. 278; authorization no. 1123/2016-PR; 2016/11/22).

Pairs of twitcher heterozygotes mice, a strain that contains a premature stop codon (W339×) in the galactosylceramidase (GALC) gene that inhibits enzymatic activity [33–35], were maintained in the housing facility. The mice were housed in plastic cages in pathogen-free room with controlled temperature (22 ± 2 °C), relative humidity (45 ± 5%) and 12/12 h light/dark cycle. Food and water were available *ad libitum* and the cages were cleaned once-twice a week.

2.2. Genotyping

The genomic DNA of 10–12 days old pups born from twitcher heterozygotes was extracted from clipped tails according to the method provided by the kit manufacturer (Sigma Aldrich, Milan, Italy).

The genotypes were determined by high resolution melting (HRM)

post-polymerase chain reaction (PCR) analysis to identify variations in the nucleic acid sequences. Genomic DNA was amplified according to the manufacturer's protocol of Type-it HRM PCR kit (Qiagen, Milan, Italy). Aliquots of genomic DNA were amplified using the following specific 5'-ATCAGACTGAAATTGGTAGACAGC-3' for forward and 5'-GCCATCAGTCAGAGCAACATAAC-3' for reverse primers.

The analysis was performed on Rotor-gene Q real-time analyzer (Corbett, Qiagen, Milan, Italy). The amplification protocol included an initial denaturation at 95 °C for 5 min, followed by 40 cycles at 95 °C for 10 s, 55 °C for 30 s, and 72 °C for 10 s. The melting analysis was performed after cycling first heating to 95 °C for 5 min, cooling to 40 °C for 1 min, heating again to 65 °C (all at 20 °C/s), and then melting at 0.1 °C/s with continuous acquisition of fluorescence until 95 °C. The Rotor gene Q software was used to calculate the derivative melting curves.

2.3. Scoring system of disease severity

In the life cycle of Krabbe-affected mice, clinical symptoms develop at the onset of the active myelination period and if untreated, they die at 35 ± 2 days. Therefore, for the experimentations, two different times of sacrifice were selected: one before the onset of symptoms (15th day, D15) and another at the terminal course of the disease (35th day, D35). The first group included six wild-type, seven heterozygous and six twitcher mice (sacrificed on D15). The second group comprised of seven wild-type, seven heterozygous and seven twitcher mice (sacrificed on D35).

During this period, starting from 8th day, the animals were monitored every 3–4 days by recording the body weight and scored for their response to coordination, hindlimb clasp and gait. The person who monitored the mice and undertook the behavioral evaluations was blinded to the genotype of the mice.

To quantify the disease severity, we used a scoring system that consists of scale 0 to 4, with 0 representing absence of the relevant KD phenotype and 4 representing the most severe manifestation. Each test was performed multiple times to ensure that the score was consistent.

Hind limb clasp is an indicator for disease progression. The mouse tail was grasped near its base, it was lifted in a space without any obstructing objects in the surrounding and the hind limb position was observed for 10 s. If the hind limbs were consistently splayed outward, away from the abdomen, it was assigned a score 0. If the hind limbs were entirely retracted and touching the abdomen for more than 75% of the time suspended, it received a score 4. Coordination and muscle function were assessed by the gait. The mouse was removed from its cage and placed on a flat surface with its head facing away from the investigator. Afterward, the assessor observed as it walked. If the mouse moved normally, with its body weight supported on all limbs, and its abdomen not touching the ground, it received a score of 0. If the mouse had difficulty moving forward and dragged its abdomen along the ground, it received a score of 4.

These procedures are capable of detecting disease severity differences between strains and within the same strain over time. The measurements collected were combined and analyzed for the composite phenotype score of each individual mouse (Table 1).

2.4. Brain tissue collection

On D15 and D35, the anesthetized mouse was placed in a heated cage for 5–10 min and first assessed for the responses to tail/toe pinches and the intactness of the ocular reflex. When the mouse is unresponsive to the noxious stimuli and the reflex is absent, it was fixed in the supine position (lying on the back with face upward) by gently tapping the forepaws and hind paws to a work surface. Thereafter, the skin was incised with surgical scissors along the thoracic midline where the thoracic field is exposed completely. The diaphragm was separated from the chest wall on both sides with scissor cuts to expose the heart. The right atrium was cut with scissors and at the first sign of blood flow,

Table 1
Scoring criteria of the KD mice in the study.

Phenotype score	Main Phenotypic signs	Phenotype description
0	No clinical sign, normal feeding, normal gait.	The mouse moves normally, with its body weight supported on all limbs, with its abdomen not touching the ground, and with both hind limbs participating evenly, and consistently splayed outward, away from the abdomen.
1	Slight tremor, normal feeding, almost normal gait.	The mouse appears to limp while walking, with one hind limb retracted toward the abdomen for less than 50% of 10 s.
2	Accentuate tremor and limp, slight weight loss, normal feeding.	The mouse manifests continuous trembling when it is stationary and both hind limbs are partially retracted toward the abdomen for less than 50% of 10 s.
3	Severe tremor, paresis of the hind limbs, weight loss equal to or slightly higher than 20%, feeding with food and water placed on the floor of the cage.	The mouse presents an uncoordinated movement and both hind limbs are partially retracted toward the abdomen for more than 50% of 10 s.
4	Paralyzed hind limbs, general weakness, weight loss higher than 20%, feeding with extreme difficulty	The mouse has difficulty moving, it drags its abdomen along the ground, and both hind limbs are retracted toward the abdomen for the time suspended of 10 s.

Phenotype presentation was classified according to a scoring system consists of scale 0 to 4. Score of 0 represents absence of the relevant phenotype and score of 4 represents the most severe manifestation.

the infusion of phosphate-buffered saline (PBS, pH 7.4) was started. Perfusion was continued until the fluid exiting the right atrium was entirely clear. Afterward, the brain tissues were removed and bisected on the sagittal plane. The brain tissues were immediately frozen on dry ice and stored at -80°C for further assays.

2.5. Isoprostanoid determination

2.5.1. Sample preparation

The brain tissue samples were homogenized (10% w/v) in PBS (pH 7.4) and then hydrolyzed by incubating the brain tissue homogenate (1 ml) in aqueous KOH (1 mM, 500 μl) at 45°C for 45 min. Afterward, the pH of the mix was adjusted to 3 by adding HCl (1 mM, 500 μl). Each sample was spiked with tetra-deuterated prostaglandin $\text{F}_{2\alpha}$ ($\text{PGF}_{2\alpha}\text{-d}_4$) (500 pg in 50 μl of ethanol), as the internal standard. Ethyl acetate (10 ml) was added to extract total lipids by vortex-mixing and centrifugation at $1000 \times g$ for 5 min at room temperature. The lipid extract was purified using solid phase extraction (SPE) as follows. Each total lipid extract was transferred to an NH_2 cartridge (500 mg Sorbent per Cartridge, 55–105 μm Particle Size, 6 cc, Waters, USA) preconditioned with hexane (5 ml). After loading, each NH_2 cartridge was sequentially washed with 10 ml of hexane:ethyl acetate (30:70, v/v), 10 ml acetonitrile:water (9:1, v/v) and 10 ml acetonitrile. The final elution was collected using a mix of ethyl acetate:methanol:acetic acid (10:85:5, v/v, 5 ml) and then dried under nitrogen at 40°C and derivatized for gas chromatography/negative ion chemical ionization tandem mass spectrometry (GC/NICI-MS/MS) analysis. In brief, the carboxylic group was converted into pentafluorobenzyl ester in the derivatization process by incubating the sample at 40°C for 45 min with pentafluorobenzyl bromide (40 μl , 10% in acetonitrile) and diisopropylethylamine (20 μl , 10% in acetonitrile). Thereafter, it was evaporated under nitrogen, and the hydroxyl groups were converted to trimethylsilyl ethers by incubating with 50 μl of N,O-bis (trimethylsilyl) trifluoroacetamide and 5 μl of diisopropylethylamine (10% in acetonitrile) for 1 h at 45°C [36–38].

2.5.2. Gas chromatography/negative ion chemical ionization tandem mass spectrometry (GC/NICI-MS/MS) analysis

The derivatized sample was injected (2 μl) for GC/NICI-MS/MS analysis. Briefly, the gas chromatograph (Trace GC and PolarisQ, Thermo/Finnigan, USA) was set at splitless mode (2 min) and the oven temperature was increased from 175°C to 270°C ($30^{\circ}\text{C}/\text{min}$). Helium was used as the carrier gas (1 ml/min) and the chromatography was performed using a SPB 1701 GC capillary column (30 m $\times$ 0.25 mm i.d., 0.25 μm film thickness, Supelco, USA). The reagent gas for the chemical ionization was methane set to 2.0 ml/min flow rate.

For total F_2 -IsoP (free plus esterified) measurements, it is based on 15-F_{2t} -IsoP which is one of the most represented isomers of the F_2 -IsoPs

[36,37]. In the analysis, the product ion was m/z 299 derived from $[\text{M} - 181]^{-}$ of the precursor ion (m/z 569).

As for $4(\text{RS})\text{-F}_{4t}\text{-NeuroP}$ ($4\text{-F}_{4t}\text{-NeuroP}$) and $10(\text{R})\text{-10-F}_{4t}\text{-NeuroP}$ + $10(\text{S})\text{-10-F}_{4t}\text{-NeuroP}$ ($10\text{-F}_{4t}\text{-NeuroP}$) the product ion was m/z 323 derived from $[\text{M} - 181]^{-}$ of the precursor ions (m/z 593) [38].

Total F_2 -dihomo-IsoP ($\text{ent-7}(\text{RS})\text{-F}_{2t}\text{-dihomo-IsoP}$ + $17\text{-F}_{2t}\text{-dihomo-IsoP}$) measurement was made by identification of the product ion m/z 327 derived from $[\text{M} - 181]^{-}$ ion of the precursor ion (m/z 597) [39].

As for the internal standard, the product ion m/z 303, derived from $[\text{M} - 181]^{-}$ of the precursor ion (m/z 573), was detected and referred to the internal standard $\text{PGF}_{2\alpha}\text{-d}_4$ [36,38,39].

Isoprostanoids quantification were carried out by relating the isoprostanoid/internal standard peak area ratio of the calibration curves constructed. The concentration points of the curve ranged from 50 pg/ml to 2 ng/ml of 15-F_{2t} -IsoPs, $4\text{-F}_{4t}\text{-NeuroP}$, $10\text{-F}_{4t}\text{-NeuroP}$, $\text{ent-7}(\text{RS})\text{-F}_{2t}\text{-dihomo-IsoP}$, or $17\text{-F}_{2t}\text{-dihomo-IsoP}$, with 500 pg $\text{PGF}_{2\alpha}\text{-d}_4$ internal standard. All samples derivatized were measured by GC/NICI-MS/MS. For each brain tissue measured, the concentration of the isoprostanoid was expressed as gram of tissue.

2.6. Chemical synthesis of $4\text{-F}_{4t}\text{-NeuroP}$, $10\text{-F}_{4t}\text{-NeuroP}$, and F_2 -dihomo-IsoP reference molecules

2.6.1. $4(\text{RS})\text{-F}_{4t}\text{-NeuroP}$, and $10(\text{R})\text{-10-F}_{4t}\text{-NeuroP}$ and $10(\text{S})\text{-10-F}_{4t}\text{-NeuroP}$ synthesis

As reported [40,41], NeuroPs and dihom-IsoPs were in-house synthesized by Institut des Biomolécules Max Mousseron (IBMM, France). Among all the F_4 -NeuroPs isomers that can be formed from non-enzymatic DHA oxidation, $4(\text{RS})\text{-4-F}_{4t}\text{-NeuroP}$ ($4\text{-F}_{4t}\text{-NeuroP}$) and $10(\text{R})\text{-10-F}_{4t}\text{-NeuroP}$ + $10(\text{S})\text{-10-F}_{4t}\text{-NeuroP}$ ($10\text{-F}_{4t}\text{-NeuroP}$) are the most represented and their clinical relevance in different neurological diseases has been recently demonstrated [38,42].

2.7. Statistical analysis

Statistical analysis was performed using the statistical software package SYSTAT, version 11 (Systat Inc., Evanston, IL, USA), and MedCalc ver. 12.0 (MedCalc. Software, Mariakerke, Belgium). Data distribution for quantitative variables was tested for normal fit (D'Agostino-Pearson test). On account of normal and non-normal data distribution, differences between groups were tested by Student's t-test, Kruskal-Wallis test, one-way analysis of variance (ANOVA), Dunnett's test, Scheffé test for all pairwise comparisons and post-hoc analyses were made. The association between variables was tested using both Spearman rank and Kendall's rank correlation tests at 95% confidence intervals (95% C.I.) for ρ and Tau coefficient, respectively. Value level of $P \leq 0.05$ was considered statistically significant. The receiver

Fig. 1. Melting curves (dF/dT) derivative of high-resolution melting (HRM): dF/dT means change in fluorescence level with increase per unit temperature change (°C). Homoduplex on the right side of the graphic represents twitcher mice; Homoduplex on the left side of the graphic represents wild-type mice; Heteroduplex represents heterozygous mice.

operating characteristic (ROC) curve analysis was performed for isoprostanoid levels measured in brain tissues to estimate the discriminative power regarding to mouse severity score.

3. Results

3.1. Genotyping

The genotypes were determined by HRM analysis. This technique allowed to distinguish the differences of DNA sequence by analyzing the melting curve path. Each duplex (homoduplex or heteroduplex) exhibited a characteristic melting curve path (Fig. 1). As shown, homoduplex of the right part of the graph confirms the genotype of twitcher mice and the left side the wild-type, and the heteroduplex of the graph affirms the genotype of the heterozygous mice. Accordingly, the mice were then divided into three groups, wild-type control mice ($n = 13$), heterozygotes mice (carriers of GALC mutations, $n = 14$) and homozygous twitcher mice ($n = 13$) for further evaluation.

3.2. Disease severity scoring

According to the scoring criteria (Table 1), the disease severity was quantified. In twitcher mice, the disease severity was progressive and significant increase from day 8 onwards ($P < 0.001$) was found. In particular, the first increase in the clinical severity scores were noticeable on day 18, where the severity score was significantly different from those measured at days 8 and 11 ($P < 0.05$). A higher disease severity score (4.0) was observed in twitcher mice at day 35. Throughout the experimental period, all wild-type and heterozygous mice were healthy and showed normal weight increase (score 0) (Fig. 2).

3.3. Levels of isoprostanoids in brain tissues

The GC/NICI-MS/MS detection of 15-F_{2t}-IsoPs, 4-F_{4t}-NeuroP, 10-F_{4t}-NeuroP, *ent*-7(RS)-F_{2t}-dihomo-IsoP and 17-F_{2t}-dihomo-IsoP was carried out in all brain samples from wild-type, heterozygous and twitcher mice.

A significant elevated concentration of F₂-IsoPs in brain tissue of the twitcher mice was found compared to wild-type and heterozygous mice. The concentration increased according to the mice phenotype where it was found to be in the following order: twitcher > heterozygous > wild-type. It is known AA is outspread in the brain white and grey matter, and any changes related to AA oxidation indicates overall oxidative damage in the brain. Our observation showed subclinical AA non-enzymatic oxidation took place in the heterozygous and twitcher

Fig. 2. Disease severity in twitcher mice from day 8 to day 34.

Data are expressed as medians (columns); bars are inter-quartile ranges (25th-75th percentiles). Kruskal-Wallis test, $P < 0.00001$. Legends: ** statistically different from days 8, 11, 15, 18, 21, 24 and 27; * statistically different from day 8, 11, 15, 18; † statistically different from days 24 and 27; ‡ statistically different from days 21 and 27; § statistically different from days 21 and 24. No variability in severity score was observed at days 8, 11, 15, 21, 24, 27 and 34.

mice, since F₂-IsoP levels in the brain were significantly higher than those detected in wild-type mice ($P < 0.05$). The level of augmentation was significantly higher in the twitcher mice compared to heterozygous mice ($P < 0.05$) (Fig. 3). There was no difference between D15 and D35 levels for all mice type.

Interestingly, F₂-dihomo-IsoP levels compared to F₂-IsoP levels appeared to be more prominent and distinctively related to KD symptoms. Higher F₂-dihomo-IsoP levels in twitcher mice brain tissues were observed at D35 as compared to those of heterozygous and wild-type at D15 and D35 ($P < 0.05$). No significant difference was detected for F₂-dihomo-IsoP levels between wild-type and heterozygous mice brain tissues, and between D15 and D35 of the respective type (Fig. 3). Regardless of the distinctive days of the disease progression and by grouping the mice according to the genotype namely wild-type, heterozygous, and twitcher alone, F₂-dihomo-IsoP levels were significantly higher in the brain tissues of twitcher mice compared to both wild-type and heterozygous mice (ANOVA test, $P < 0.001$; Scheffé test for all pairwise comparisons, $P < 0.05$). However, F₂-dihomo-IsoP levels showed no significant difference between heterozygous and wild-type mice (data not shown).

Fig. 3. F₂-IsoP and F₂-dihomo-IsoP levels in whole brain tissue from wild-type, heterozygote and homozygous twitcher mice at day 15 and day 35 of the life cycle, respectively.

Panel A: Kruskal-Wallis test, $P < 0.0001$; Panel B: Kruskal-Wallis test, $P < 0.01$.

Data ($n = 40$) are expressed as medians (columns); bars are inter-quartile ranges (25th-75th percentiles). Asterisks indicate significant pairwise tests, $P < 0.05$. Wt: wild-type; Ht: heterozygote; Tw: twitcher; D15: day 15; D35: day 35.

Fig. 4. F₄-NeuroP (sum of 4-F₄-NeuroP and 10-F₄-NeuroP), 4-F₄-NeuroP and 10-F₄-NeuroP levels in whole brain tissue from wild-type, heterozygote and homozygous twitcher animals at day 15 and day 35 of the life cycle, respectively.

Panel A: Kruskal-Wallis test, $P = 0.0001$; Panel B: Kruskal-Wallis test, $P = 0.0001$; Panel C: Kruskal-Wallis test, $P = 0.0001$.

Data ($n = 40$) are expressed as medians (columns); bars are inter-quartile ranges (25th-75th percentiles). Asterisks indicate significant pairwise tests, $P < 0.05$. Wt: wild-type; Ht: heterozygote; Tw: twitcher; D15: day 15; D35: day 35.

The concentration of F₄-NeuroPs in the brain tissues differed between the mice symptoms where it was found to be twitcher > heterozygous > wild-type. Total, F₄-NeuroP (4-F₄-NeuroP + 10-F₄-NeuroP) brain tissue levels were significantly higher in twitcher mice at

D35 as compared to D15 and D35 wild-type and heterozygous mice. The levels of F₄-NeuroP in the brain tissue did not differ in the disease progression (D15 vs D35) for all mice genotypes (Fig. 4). When differentiating the isomeric type for F₄-NeuroPs, the concentration of 4-F₄-

NeuroP and 10-F_{4t}-NeuroP at D15 and D35 in twitcher mice were not statistically different. In the brain tissues of heterozygous mice, 4-F_{4t}-NeuroP levels were significantly different between D15 and D35 whereas no difference was found for 10-F_{4t}-NeuroP levels. However, concentrations of 10-F_{4t}-NeuroP in the brain tissues of all mice genotypes were 2–3 folds higher than 4-F_{4t}-NeuroP. In addition, regardless of the distinctive days of the disease progression and by grouping the mice according to wild-type, heterozygous, and twitcher genotypes, the brain tissues of twitcher mice had significantly higher 4-F_{4t}-NeuroP and 10-F_{4t}-NeuroP levels compared to heterozygous and wild-type (ANOVA test, $P < 0.001$; Scheffé test for all pairwise comparisons, $P < 0.05$). Further for 10-F_{4t}-NeuroP levels, statistical significance was found between wild-type and heterozygous mice type (ANOVA test, $P < 0.001$; Scheffé test for all pairwise comparisons, $P < 0.05$) but not for 4-F_{4t}-NeuroP levels (data not shown).

The following isoprostanoid levels were found to be significantly correlated to each other: F₂-IsoPs vs total F₄-NeuroPs ($\rho = 0.598$, $P < 0.0001$, 95% C.I. for ρ : 0.352 to 0.766; Kendall's Tau coefficient = 0.417, $P = 0.0002$, 95% C.I. for Tau: 0.233 to 0.570; $n = 40$); F₂-IsoPs vs total F₂-dihomo-IsoPs ($\rho = 0.440$, $P = 0.0045$, 95% C.I. for ρ : 0.149 to 0.661; Kendall's Tau coefficient = 0.330, $P = 0.0028$, 95% C.I. for Tau: 0.0788 to 0.541; $n = 40$); total F₄-NeuroPs vs total F₂-dihomo-IsoPs ($\rho = 0.675$, $P < 0.0001$, 95% C.I. for ρ : 0.460 to 0.815; Kendall's Tau coefficient = 0.510, $P < 0.0001$, 95% C.I. for Tau: 0.332 to 0.661; $n = 40$).

3.4. Brain isoprostanoids and disease severity

Relationships between disease progression and non-enzymatic PUFA oxidation were determined by correlation of disease severity and isoprostanoids levels. In twitcher mice ($n = 13$), the severity score was significantly correlated to F₂-dihomo-IsoPs ($\rho = 0.54$, $P = 0.057$, 95% C.I. for ρ : 0.0163 to 0.841; Kendall's Tau coefficient = 0.437, $P = 0.044$, 95% C.I. for Tau: 0.00479 to 0.724) and 4-F_{4t}-NeuroPs ($\rho = 0.581$, $P = 0.037$, 95% C.I. for ρ : 0.044 to 0.857; Kendall's Tau coefficient = 0.481, $P = 0.026$, 95% C.I. for Tau: 0.0157 to 0.822) levels in the brain tissues (Fig. 5). No significant correlations with severity score were found for total F₂-IsoPs, 10-F_{4t}-NeuroP and total F₄-NeuroPs (data not shown).

ROC curve analysis showed significant specificity and sensitivity of each isoprostanoid (total F₂-IsoPs, total F₂-dihomo-IsoPs, 4-F_{4t}-NeuroP, 10-F_{4t}-NeuroP and total F₄-NeuroPs) amount to discriminate mice with severity score ≥ 1 from those with severity score of 0. The cut-off value

was calculated for each isoprostanoid class. A summary of the test is shown in Table 2.

4. Discussion

Activation of the immune system and neuroinflammation are related to the pathogenesis of KD [43–45]. These are sources of ROS and potentially accumulate, leading to oxidative stress. Accordingly, neuroinflammatory processes are suggested to play a key role for oxidative damage to the brain. PUFAs, especially AA, AdA and DHA are rich in the brain and prone to oxidation [17,22,46,47]. Depending on the degree of oxidative stress, a mixture of oxidized molecules are released that may be protective, cytotoxic to the neural cells or idle without significant pathogenic purpose. Psychosine-induced damage in KD appears to be redox sensitive and reducible by antioxidant defenses [48,49] and therefore appropriate to consider its relationship with oxidative damage.

Non-enzymatic ROS/free radical oxidation of AA, AdA and DHA release unique set of molecules known as isoprostanoids that potentially serve as phenotypical characterization in neurological diseases [17,19,22,50,51] and in current experimental KD. Specific isoprostanoids are released depending on the type of PUFA. Under oxidative stress, AA, which is non-specifically disseminated in the brain, releases F₂-IsoPs whereas brain white matter enriched AdA generates F₂-dihomo-IsoPs, and DHA brain grey matter enriched DHA releases F₄-NeuroPs [17,22].

Esch et al. laid the foundations for a lipidomic approach in KD [52], and further suggested PUFA in the profile can track KD disease progression [16]. Moreover, the relevance of PUFAs to brain function is widely documented [7–9]. Long-chain PUFAs are abundant in brain, and the occurrence of neurogenesis, expansion of glial cells and neurons, as well as nerve myelination, strongly depend on the presence of long-chain PUFAs [10–12]. Among long-chain PUFAs, AA and DHA are essential for neurogenesis and hippocampal development [13,53]. Neuroplasticity and monoaminergic transmission are also closely related to PUFA profile [10,54,55]. In addition, fatty acids are required in ceramide formation of the neural cells and alterations of these fatty acids in the myelin lipids have been related to neurological dysfunction [56,57].

In this study, we showed that the twitcher mice were under oxidative stress and that non-enzymatic oxidation of AA, AdA and DHA was consistently notable and the process predominantly occurred for AA and DHA. Our observation also showed oxidative damage took place since a specific relationship between isoprostanoid levels and the KD

Fig. 5. Relationship between isoprostanoid levels in brain tissue and disease severity.

Panel A: Scattergrams for brain F₂-dihomo-IsoP levels and disease severity. Panel B: Scattergrams for brain 4-F_{4t}-NeuroP levels and disease severity. The association between variables was tested using both Spearman rank and Kendall's rank correlation tests at 95% confidence intervals (95% C.I.) for ρ and Tau coefficient respectively. The parameters of the significant relationships are described in the Results.

Table 2
ROC analysis for brain isoprostanoid content and disease severity.

Mice group with assigned severity score of 0 (n = 31) and Mice group with assigned severity score ≥ 1 (n = 9)						
Isoprostanoid class	Cut-off value (ng/g)	Sensitivity (%)	Specificity (%)	+ PV (%)	- PV (%)	P value
Total F ₂ -IsoPs	> 11.2	100.00	90.32	75	100	< 0.0001
Total F ₂ -dihomo-IsoPs	> 3.1	88.89	80.65	57.1	96.2	< 0.0001
4-F _{4t} -NeuroP	> 3.9	66.67	100	100	91.2	< 0.0001
10-F _{4t} -NeuroP	> 7.9	100	61.29	42.9	100	< 0.0001
Total F ₄ -NeuroPs	> 10.6	100	64.52	45.0	100	< 0.0001

+ P.V.: positive predictive value; -P.V.: negative predictive value.

disease severity was highlighted. In fact, 4F_{4t}-NeuroP was closely related to the disease parameters. This observation suggests the relevance of a brain gray matter damage and the differentiation between disease phenotypes, in particular when comparing the heterozygous mice with homozygous twitcher mice.

Studies showed an alteration of the brain matter in KD was associated to unexpected neuronal defects and myoclonic seizures [58,59]. Moreover, a distinctive feature for the proposed relationship between PUFA oxidative process and pathogenetic pathways appears to be confirmed by the different abundance of the two distinct F₄-NeuroP isomers (4-F_{4t}-NeuroP and 10-F_{4t}-NeuroP). Previously, it was reported that *in vivo* DHA oxidation follows preferential chemical rearrangements according to different neurological diseases. In particular, plasma levels of 4-F_{4t}-NeuroP and 10-F_{4t}-NeuroP were shown to be related to clinical severity of these diseases (multiple sclerosis, autism spectrum disorders, Rett syndrome, and Down syndrome) and distinctive for different neurological conditions [38]. In the investigated KD mouse model, 10-F_{4t}-NeuroP appears to be the preferential F₄-NeuroP isomer to be formed in the brain DHA oxidation process of the twitcher mice.

Intriguingly, F₂-dihomo-IsoP levels were distinctively elevated in twitcher mice but not in wild-type and heterozygous mice. Thus, F₂-dihomo-IsoP levels appear to be a biochemical data to reflect the degree of the brain white matter damage, by oxidative stress and plausible to be a contributing factor of KD symptomatology. It is suggested that F₂-dihomo-IsoPs may be a novel marker for gene-related diseases, where we found it to represent an early marker of the disease in Rett Syndrome, a pervasive neurodevelopment disorder mainly caused by mutations in the methyl-CpG binding protein 2 (*MeCP2*) gene [39]. Moreover, different from KD, no significant changes of F₂-dihomo-IsoP levels in brain tissue were observed in symptomatic *Mecp2* $-/\gamma$ mice, where an increased PUFA oxidation was revealed in the neurons but not in astrocytes [37].

A further interesting fact stemming from the present study is the significant increase in F₂-IsoP and F₄-NeuroP levels in the brain of heterozygous mice as it seems to be asymptomatic. In reference to the autosomal recessive disease, the severity score for heterozygotes mice was comparable to that reported for wild-type mice. A possible explanation for the difference in oxidative stress markers between wild-type and heterozygotes groups is that isoprostanoids appeared to be a part of the phenotype that mirrors KD severity when a cut off value is reached. Therefore, our observation in the increased levels of non-enzymatic PUFA products is not pre-empting when considering other recessive genetic disorders. Although carriers of recessive mutations are not clinically ill, altered clinical features and biochemical values can be evidenced. Within this context, high serum creatine kinase levels are reported in majority of dystrophinopathy carriers and cardiomyopathy can be detected in female carriers without any symptoms [60]. Likewise, minor individuals of thalassemia are generally considered healthy. Nevertheless, the prognosis of thalassemia minor carriers is suggested to be affected by iron overload and anaemia [61], features of thalassemia related to oxidative stress [62,63]. Indeed, thalassemia carriers are identifiable using red cell indices [64] and screening for thalassemia is based on a complete blood count and hemoglobin

characterization [65]. When considering KD, the reported increased damage to AA and DHA in twitcher mice agree with the update of a quite recent review showing that heterozygous carriers of KD-causing mutations exhibit increased risk of developing other complications such as multiple sclerosis [66]. This could confirm the hypothesis that the formation of isoprostanoids below a certain threshold value may not lead to immediate symptomatology but on the long term may be involved in development of other pathogenesis.

Although antioxidant treatments have been suggested to be able to counteract the psychosine damage and KD disease progression [48,49,67], potential therapeutic perspective could be viewed from the role of isoprostanoids in eliciting different molecular mechanism pathways [27,68]. Insofar, it is known that isoprostanates mediate biological effects by interacting with prostanoid receptors, such as thromboxane receptor [68,69].

In conclusion, a key role for PUFA oxidative damage to brain gray and white matter in the pathogenesis and progression of KD is reported shedding new insights on the biochemical indexes of KD and providing novel information for potential therapeutic targets.

Funding

This study was partially supported by Italian Association for Leucodystrophy of Krabbe "Progetto Grazia", and by funds for basic research "Ruolo dello stress ossidativo e di molecole antiossidanti nella sindrome di Rett".

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments

This research is dedicated to Krabbe disease patients and their families.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.freeradbiomed.2019.05.014>.

References

- [1] D.A. Wenger, M.A. Rafi, P. Luzi, Krabbe disease: one Hundred years from the bedside to the bench to the bedside, *J. Neurosci. Res.* 94 (2016) 982–989.
- [2] J.S. Won, A.K. Singh, I. Singh, Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease, *J. Neurosci. Res.* 94 (2016) 990–1006.
- [3] K.H. Cho, M.W. Kim, S.U. Kim, Tissue culture model of Krabbe's disease: psychosine cytotoxicity in rat oligodendrocyte cultures, *Dev. Neurosci.* 19 (1997) 321–327.
- [4] S. Sugama, S.U. Kim, H. Ida, Y. Eto, Psychosine cytotoxicity in rat neural cell cultures and protection by phorbol ester and dimethyl sulfoxide, *Pediatr. Res.* 28 (1990) 473–476.
- [5] R. Avola, A.C. Graziano, G. Pannuzzo, E. Alvares, V. Cardile, Krabbe's leukodystrophy: approaches and models in vitro, *J. Neurosci. Res.* 94 (2016) 1284–1292.
- [6] S. Giri, M. Khan, R. Rattan, I. Singh, A.K. Singh, Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death, *J. Lipid Res.* 47 (2006) 1478–1492.
- [7] H. Bentsen, Dietary polyunsaturated fatty acids, brain function and mental health, *Microb. Ecol. Health Dis.* 28 (sup1) (2017) 1281916.

- [8] T. Wysoczański, E. Sokoła-Wysoczańska, J. Pękala, S. Lochyński, K. Czyż, R. Bodkowski, G. Herbinger, B. Patkowska-Sokoła, T. Librowski, Omega-3 fatty acids and their role in central nervous system - a review, *Curr. Med. Chem.* 23 (2016) 816–831.
- [9] D.J. Bos, S.J. van Montfort, B. Oranje, S. Durston, P.A. Smeets, Effects of omega-3 polyunsaturated fatty acids on human brain morphology and function: what is the evidence? *Eur. Neuropsychopharmacol.* 26 (2016) 546–561.
- [10] R. Crupi, A. Marino, S. Cuzzocrea, n-3 fatty acids: role in neurogenesis and neuroplasticity, *Curr. Med. Chem.* 20 (2013) 2953–2963.
- [11] K.B. Hadley, A.S. Ryan, S. Forsyth, The essentiality of arachidonic acid in infant development, *Nutrients* 8 (2016) 216.
- [12] C.I. Janssen, A.J. Kiliaan, Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration, *Prog. Lipid Res.* 53 (2014) 1–17.
- [13] E. Kawakita, M. Hashimoto, O. Shido, Docosahexaenoic acid promotes neurogenesis in vitro and in vivo, *Neuroscience* 139 (2006) 991–997.
- [14] S.E. Hancock, M.G. Friedrich, T.W. Mitchell, R.J. Truscott, P.L. Else, Decreases in phospholipids containing adrenic and arachidonic acids occur in the human Hippocampus over the adult lifespan, *Lipids* 50 (2015) 861–872.
- [15] A.C. Graziano, V. Cardile, History, genetic, and recent advances on Krabbe disease, *Gene* 555 (2015) 2–13.
- [16] A. Zanfini, E. Dreassi, A. Berardi, P. Piomboni, E. Costantino-Cecarini, A. Luddi, GC-EL-MS analysis of fatty acid composition in brain and serum of twitcher mouse, *Lipids* 49 (2014) 1115–1125.
- [17] C. Signorini, C. De Felice, J.M. Galano, C. Oger, S. Leoncini, A. Cortelazzo, L. Ciccoli, T. Durand, J. Hayek, J.C. Lee, Isoprostanooids in clinical and experimental neurological disease models, *Antioxidants (Basel)* 7 (2018) E88.
- [18] C. Signorini, C. De Felice, T. Durand, C. Oger, J.M. Galano, S. Leoncini, A. Pecorelli, G. Valacchi, L. Ciccoli, J. Hayek, Isoprostanes and 4-hydroxy-2-nonenal: markers or mediators of disease? Focus on Rett syndrome as a model of autism spectrum disorder, 2013, *Oxid. Med. Cell. Longev.* 2013 (2013) 34382410 pages <http://dx.doi.org/10.1155/2013/343824>.
- [19] T. Durand, C. De Felice, C. Signorini, C. Oger, V. Bultel-Poncé, A. Guy, J.M. Galano, S. Leoncini, L. Ciccoli, A. Pecorelli, G. Valacchi, J. Hayek, F(2)-Dihomo-isoprostanes and brain white matter damage in stage 1 Rett syndrome, *Biochimie* 95 (2013) 86–90.
- [20] L. Jourard-Cubizolles, J.C. Lee, C. Vigor, H.H. Leung, J. Bertrand-Michel, J.M. Galano, A. Mazur, T. Durand, C. Gladine, Insight into the contribution of isoprostanooids to the health effects of omega 3 PUFAs, *Prostag. Other Lipid Mediat.* 133 (2017) 111–122.
- [21] M. Czernska, M. Zieliński, J. Gromadzińska, Isoprostanes - a novel major group of oxidative stress markers, *Int. J. Occup. Med. Environ. Health* 29 (2016) 179–190.
- [22] J.M. Galano, J.C. Lee, C. Gladine, B. Comte, J.Y. Le Guennec, C. Oger, T. Durand, Non-enzymatic cyclic oxygenated metabolites of adrenic, docosahexaenoic, eicosapentaenoic and α -linolenic acids; bioactivities and potential use as biomarkers, *Biochim. Biophys. Acta* 1851 (2015) 446–455.
- [23] L. Minghetti, R. Salvi, M. Lavinia Salvatori, M.A. Ajmone-Cat, C. De Nuccio, S. Visentin, V. Bultel-Poncé, C. Oger, A. Guy, J.M. Galano, A. Greco, A. Bernardo, T. Durand, Nonenzymatic oxygenated metabolites of α -linolenic acid B1- and L1-phytylprostanates protect immature neurons from oxidant injury and promote differentiation of oligodendrocyte progenitors through PPAR- γ activation, *Free Radic. Biol. Med.* 73 (2014) 41–50.
- [24] J. Roy, J. Fauconnier, C. Oger, C. Farah, C. Angebault-Prouteau, J. Thireau, P. Bideaux, V. Scheuermann, V. Bultel-Poncé, M. Demion, J.M. Galano, T. Durand, J.C. Lee, J.Y. Le Guennec, Non-enzymatic oxidized metabolite of DHA, 4(RS)-4-F (4t)-neuroprostanate protects the heart against reperfusion injury, *Free Radic. Biol. Med.* 102 (2017) 229–239.
- [25] M. VanRollins, R.L. Woltjer, H. Yin, J.D. Morrow, T.J. Montine, F2-dihomo-isoprostanes arise from free radical attack on adrenic acid, *J. Lipid Res.* 49 (2008) 995–1005.
- [26] E.E. Reich, W.R. Markesbery, L.J. Roberts 2nd, L.L. Swift, J.D. Morrow, T.J. Montine, Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanates in Alzheimer's disease, *Am. J. Pathol.* 158 (2001) 293–297.
- [27] E. Miller, A. Morel, L. Saso, J. Saluk, Isoprostanes and neuroprostanates as biomarkers of oxidative stress in neurodegenerative diseases, *Oxid. Med. Cell. Longev.* 2014 (2014) 572491.
- [28] P.S. Sastry, Lipids of nervous tissue: composition and metabolism, *Prog. Lipid Res.* 24 (1985) 69–176.
- [29] J.A. Hawkins-Salsbury, E.Y. Qin, A.S. Reddy, C.A. Vogler, M.S. Sands, Oxidative stress as a therapeutic target in globoid cell leukodystrophy, *Exp. Neurol.* 237 (2012) 444–452.
- [30] E. Cavalca, M. Cesani, J.C. Gifford, M. Sena-Esteves, M.R. Terreni, G. Leoncini, M. Peviani, A. Biffi, Metallothioneins are neuroprotective agents in lysosomal storage disorders, *Ann. Neurol.* 83 (2018) 418–432.
- [31] A. Del Grosso, S. Antonini, L. Angella, I. Tonazzini, G. Signore, M. Cecchini, Lithium improves cell viability in psychosine-treated MO3.13 human oligodendrocyte cell line via autophagy activation, *J. Neurosci. Res.* 94 (2016) 1246–1260.
- [32] N.I. Weinstock, L. Wrabetz, M.L. Feltri, D. Shin, Metabolic profiling reveals biochemical pathways and potential biomarkers associated with the pathogenesis of Krabbe disease, *J. Neurosci. Res.* 94 (2016) 1094–1107.
- [33] T. Kobayashi, T. Yamanaka, J.M. Jacobs, F. Teixeira, K. Suzuki, The Twitcher mouse: an enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease), *Brain Res.* 202 (1980) 479–483.
- [34] N. Sakai, K. Inui, N. Tatsumi, H. Fukushima, T. Nishigaki, M. Taniike, J. Nishimoto, H. Tsukamoto, I. Yanagihara, K. Ozono, S. Okada, Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease, *J. Neurochem.* 66 (1996) 1118–1124.
- [35] K. Suzuki, K. Suzuki, The twitcher mouse: a model for Krabbe disease and for experimental therapies, *Brain Pathol.* 5 (1995) 249–258.
- [36] C. Signorini, L. Ciccoli, S. Leoncini, S. Carloni, S. Perrone, M. Comporti, W. Balduini, G. Buonocore, Free iron, total F-isoprostanes and total F-neuroprostanates in a model of neonatal hypoxic-ischemic encephalopathy: neuroprotective effect of melatonin, *J. Pineal Res.* 46 (2009) 148–154.
- [37] C. De Felice, F. Della Ragione, C. Signorini, S. Leoncini, A. Pecorelli, L. Ciccoli, F. Scalabrì, F. Marracino, M. Madonna, G. Belmonte, L. Ricceri, B. De Filippis, G. Laviola, G. Valacchi, T. Durand, J.M. Galano, C. Oger, A. Guy, V. Bultel-Poncé, J. Guy, S. Filosa, J. Hayek, M. D'Esposito, Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome, *Neurobiol. Dis.* 68 (2014) 66–77.
- [38] C. Signorini, C. De Felice, T. Durand, J.M. Galano, C. Oger, S. Leoncini, L. Ciccoli, M. Carone, M. Ulivelli, C. Manna, A. Cortelazzo, J.C. Lee, J. Hayek, Relevance of 4-F (4t)-neuroprostanate and 10-F(4t)-neuroprostanate to neurological diseases, *Free Radic. Biol. Med.* 115 (2018) 278–287.
- [39] C. De Felice, C. Signorini, T. Durand, C. Oger, A. Guy, V. Bultel-Poncé, J.M. Galano, L. Ciccoli, S. Leoncini, M. D'Esposito, S. Filosa, A. Pecorelli, G. Valacchi, J. Hayek, F2-dihomo-isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome, *J. Lipid Res.* 52 (2011) 2287–2297.
- [40] C. Oger, V. Bultel-Poncé, A. Guy, L. Balas, J.C. Rossi, T. Durand, J.M. Galano, The handy use of Brown's P2-Ni catalyst for a skipped diyne deuteration: application to the synthesis of a [D4]-labeled F4t-neuroprostanate, *Chemistry* 16 (2010) 13976–13980.
- [41] A. Guy, C. Oger, J. Heppelkous, C. Signorini, C. De Felice, A. Fürstner, T. Durand, J.M. Galano, Oxygenated metabolites of n-3 polyunsaturated fatty acids as potential oxidative stress biomarkers: total synthesis of 8-F3t-IsoP, 10-F4t-NeuroP and [D4]-10-F4t-NeuroP, *Chemistry* 20 (2014) 6374–6380.
- [42] J.M. Galano, Y.Y. Lee, C. Oger, C. Vigor, J. Vercauteren, T. Durand, M. Giera, J.C. Lee, Isoprostanes, neuroprostanates and phytylprostanates: an overview of 25 years of research in chemistry and biology, *Prog. Lipid Res.* 68 (2017) 83–108.
- [43] S. Karumthil-Melethil, S.J. Gray, Immunological considerations for treating globoid cell leukodystrophy, *J. Neurosci. Res.* 94 (2016) 1349–1358.
- [44] G.B. Potter, M.A. Petryniak, Neuroimmune mechanisms in Krabbe's disease, *J. Neurosci. Res.* 94 (2016) 1341–1348.
- [45] M.E. Figueiredo-Pereira, P. Rockwell, T. Schmidt-Glenewinkel, P. Serrano, Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration, *Front. Mol. Neurosci.* 7 (2015) 104.
- [46] S.M. Raefsky, R. Furman, G. Milne, E. Pollock, P. Axelsen, M.P. Mattson, M.S. Shchepinov, Deuterated polyunsaturated fatty acids reduce brain lipid peroxidation and hippocampal amyloid β -peptide levels, without discernible behavioral effects in an APP/PS1 mutant transgenic mouse model of Alzheimer's disease, *Neurobiol. Aging* 66 (2018) 165–176.
- [47] W. Maruyama, M. Shaomoto-Nagai, Y. Kato, S. Hisaka, T. Osawa, M. Naoi, Role of lipid peroxide in the neurodegenerative disorders, in: Y. Kato (Ed.), *Lipid Hydroperoxide-Derived Modification of Biomolecules. Subcellular Biochemistry*, Springer, Dordrecht, 2014, pp. 127–136.
- [48] E. Haq, S. Giri, I. Singh, A.K. Singh, Molecular mechanism of psychosine-induced cell death in human oligodendrocyte cell line, *J. Neurochem.* 86 (2003) 1428–1440.
- [49] M. Khan, E. Haq, S. Giri, I. Singh, A.K. Singh, Peroxisomal participation in psychosine-mediated toxicity: implications for Krabbe's disease, *J. Neurosci. Res.* 80 (2005) 845–854.
- [50] G.L. Milne, Q. Dai, L.J. Roberts 2nd, The isoprostanes-25 years later, *Biochim. Biophys. Acta* 1851 (2015) 433–445.
- [51] C. Signorini, C. De Felice, S. Leoncini, R.S. Møller, G. Zollo, S. Buoni, A. Cortelazzo, R. Guerranti, T. Durand, L. Ciccoli, M. D'Esposito, K. Ravn, J. Hayek, MECP2 duplication syndrome: evidence of enhanced oxidative stress. A comparison with Rett syndrome, *PLoS One* 11 (2016) e0150101.
- [52] S.W. Esch, T.D. Williams, S. Biswas, A. Chakrabarty, S.M. LeVine, Sphingolipid profile in the CNS of the twitcher (globoid cell leukodystrophy) mouse: a lipidomics approach, *Cell. Mol. Biol. (Noisy-Le-Grand)* 49 (2003) 779–787.
- [53] H. Tokuda, M. Kontani, H. Kawashima, Differential effect of arachidonic acid and docosahexaenoic acid on age-related decreases in hippocampal neurogenesis, *Neurosci. Res.* 88 (2014) 58–66.
- [54] F. Darios, B. Davletov, Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3, *Nature* 440 (2006) 813–817.
- [55] S. Chalou, S. Vancassel, L. Zimmer, D. Guilleto, G. Durand, Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission, *Lipids* 36 (2001) 937–944.
- [56] L. Colombaioni, M. Garcia-Gil, Sphingolipid metabolites in neural signalling and function, *Brain Res. Rev.* 46 (2004) 328–355.
- [57] V. Filippov, M.A. Song, K. Zhang, H.V. Vinters, S. Tung, W.M. Kirsch, J. Yang, P.J. Duerksen-Hughes, Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases, *J. Alzheimer's Dis.* 29 (2012) 537–547.
- [58] E.R. Bongarzone, M.L. Escobar, S.J. Gray, T. Kafri, C.H. Vite, M.S. Sands, Insights into the pathogenesis and treatment of Krabbe disease, *Pediatr. Endocrinol. Rev.* 13 (Suppl 1) (2016) 689–696.
- [59] L.E. Morse, N.P. Rosman, Myoclonic seizures in Krabbe disease: a unique presentation in late-onset type, *Pediatr. Neurol.* 35 (2006) 154–157.
- [60] K. Adachi, S. Hashiguchi, M. Saito, S. Kashiwagi, T. Miyazaki, H. Kawai, H. Yamada, T. Iwase, M. Akaike, S. Takao, M. Kobayashi, M. Ishizaki, T. Matsui, M. Mori-Yoshimura, E. Kimura, Detection and management of cardiomyopathy in female dystrophinopathy carriers, *J. Neurol. Sci.* 386 (2018) 74–80.
- [61] L. Graffeo, A. Vitranio, S. Scodotto, G. Dardanoni, M.S. Pollina Addario, A. Giambona, M. Sacco, R. Di Maggio, D. Renda, F. Taormina, A. Triveri,

- M. Attanasio, C. Gluud, A. Maggio, β -Thalassemia heterozygote state detrimentally affects health expectation, *Eur. J. Intern. Med.* 54 (2018) 76–80.
- [62] L. Ciccoli, C. Signorini, C. Scarano, V. Rossi, S. Bambagioni, M. Ferrali, M. Comporti, Iron release in erythrocytes from patients with beta-thalassemia, *Free Radic. Res.* 30 (1999) 407–413.
- [63] C. Matayatsuk, C.Y. Lee, R.W. Kalpravidh, P. Sirankapracha, P. Wilairat, S. Fucharoen, B. Halliwell, Elevated F2-isoprostanes in thalassemic patients, *Free Radic. Biol. Med.* 43 (2007) 1649–1655.
- [64] O. Tangvarasittichai, N. Poonanan, S. Tangvarasittichai, Using red cell indices and reticulocyte parameters for carrier screening of various thalassemia syndromes, *Indian J. Clin. Biochem.* 32 (2017) 61–67.
- [65] S. Langlois, J.C. Ford, D. Chitayat, CCMG prenatal diagnosis committee; socg genetics committee, carrier screening for thalassemia and hemoglobinopathies in Canada, *J. Obstet. Gynaecol. Can.* 30 (2008) 950–959.
- [66] N.J. Scott-Hewitt, C.J. Folts, M.D. Noble, Heterozygous carriers of galactocerebrosidase mutations that cause Krabbe disease have impaired microglial function and defective repair of myelin damage, *Neural Regen. Res.* 13 (2018) 393–401.
- [67] G. Pannuzzo, V. Cardile, E. Costantino-Ceccarini, E. Alvares, D. Mazzone, V. Perciavalle, A galactose-free diet enriched in soy isoflavones and antioxidants results in delayed onset of symptoms of Krabbe disease in twitcher mice, *Mol. Genet. Metab.* 100 (2010) 234–2340.
- [68] J.M. Galano, E. Mas, A. Barden, T.A. Mori, C. Signorini, C. De Felice, A. Barrett, C. Opere, E. Pinot, E. Schwedhelm, R. Benndorf, J. Roy, J.Y. Le Guennec, C. Oger, T. Durand, Isoprostanes and neuroprostanes: total synthesis, biological activity and biomarkers of oxidative stress in humans, *Prostag. Other Lipid Mediat.* 107 (2013) 95–102.
- [69] E. Lauretti, A. Di Meco, J. Chu, D. Praticò, Modulation of AD neuropathology and memory impairments by the isoprostane F2 α is mediated by the thromboxane receptor, *Neurobiol. Aging* 36 (2015) 812–820.